21 CFR Part 11 Explained: Complete Guide to FDA Electronic Records & Signatures (2026) By PharmaShare CSV Team | Data Integrity | August 2026 Quick Summary: 21 CFR Part 11 is FDA rule for accepting electronic records & signatures as equivalent to paper. Applies if you use computers in GMP/GLP/GCP. Requires Audit Trail, Electronic Signature … Read more
505(b)(2) vs ANDA: Which Filing Should You Choose? Complete Comparison 2026 By PharmaShare Regulatory Team | US FDA Pathways | August 2026 Quick Answer: ANDA is for exact copy of brand (same dose, same form). 505(b)(2) is for modified version – new strength, new form, new route, new indication. ANDA is cheap & fast ($2-5M). … Read more
What is 180-Day Exclusivity in US? The $100 Million Prize for First Generic By PharmaShare Regulatory Team | US FDA Generic Strategy | August 2026 Quick Answer: 180-Day Exclusivity is a 6-month monopoly given by USFDA to the First Company that files an ANDA with Para IV challenge and wins. For those 180 days, FDA … Read more
What is Orange Book & How to Read It? Complete Guide for Generic Pharma By PharmaShare Regulatory Team | US FDA Regulatory | August 2026 Quick Answer: Orange Book is the FDA’s official list of all approved drugs + their patents + exclusivity + generic equivalents. If you work in Regulatory, R&D, IP or Business … Read more
Types of ANDA Filing in the US: Para I, II, III, IV Explained with Examples By PharmaShare Regulatory Team | US FDA Regulatory Affairs | August 2026 Quick Answer: An ANDA can be filed under 4 Paragraph Certifications (I, II, III, IV). Your Para filing decides if you launch immediately, wait for patent expiry, or … Read more
Role of Rejection Verification Sensor in Pharma Packing Lines: Why Your Auto-Reject is Useless Without It By PharmaShare Editorial Team | Pharma Packaging Technology | August 2026 Quick Answer: Rejection Verification Sensor confirms that a blister/bottle/carton that was detected as defective was ACTUALLY physically removed from the line. Without it, your vision system, checkweigher, metal … Read more
Non-Fill Detector in Blister Packing Operation: Working, Validation & GMP Guide By PharmaShare | OSDF Packing Series | August 2026 Non-Fill Detector is a vision / sensor system on blister machines that detects EMPTY pockets and rejects the blister automatically. Without it, empty blister = Market Complaint + FDA 483. 1. What is a Non-Fill … Read more
Handling of Rejects During Packing in Pharma: GMP Compliance Guide for Oral Solid Dosage Forms By PharmaShare | Last Updated: August 2026 In pharma packing, “reject” doesn’t mean “waste”. Every rejected blister, bottle, or tablet is data. It tells you what went wrong on your line. If rejects are not handled properly, you risk: mix-ups, … Read more
Why More Count Variation Complaints Are Reported in Controlled Substance Products By PharmaShare Team | Last Updated: August 16, 2026 | Category: Controlled Substances, Complaints, QA, Regulatory, GMP, Packaging “Bottle of Alprazolam 1mg – Label claim 100, Received 99” “Bottle of Tramadol – Short by 1 capsule” Have you noticed? Count variation complaints are 5x … Read more
Count Variation Complaints in Pharma: Root Causes, CAPA & Prevention By PharmaShare Team | Last Updated: August 16, 2026 | Category: Complaints, QA, Packaging, GMP, CAPA, Pharma “Customer received 98 tablets instead of 100” “This is the 3rd complaint for short fill this month” Count variation complaints are one of the most common and serious … Read more
